Diagnosis was confirmed by bone marrow aspiration and biopsy. This study included 30 patients with multiple myeloma. Herein, this is a retrospective study including patients with myeloma and analyzing patients’ prognosis post transplantation to discover possible prognostic factors that affect the efficacy of transplantation and to make a guidance for future clinical work. In order to prevent the poor outcome of the HSCT treatment for multiple myeloma, researchers have attempted to identify significant prognostic factors which may be modified in the future ( 6- 9).
Alternatively, autologous HSCT (Auto-HSCT) is widely utilized to make a balance between the risks and benefits as its efficacy is superior to conventional chemotherapy and its safety is better than Allo-HSCT, despite that it has a high recurrence rate that cannot be ignored ( 5). Therein, allogeneic HSCT (Allo-HSCT) is a strong consideration for myeloma patients of a high-risk stage, however, its application is somehow limited due to its extremely high potential of transplant-related mortality ( 4). Notably, hematopoietic stem cell transplantation (HSCT) has been applied to a number of hematopoietic diseases, including leukemia, lymphoma, and myeloma, as well as other solid tumors and non-malignant disorders for almost 60 years ( 3). Unfortunately, like other hematopoietic malignancies, multiple myeloma cannot be completely cured by conventional chemotherapies ( 2). Conventional chemotherapy is favorably considered as a valid action to improve the clinical symptoms and survival rate of patients. It develops when plasmocytes undergo genetic mutations due to a variety of factors ( 1). Multiple myeloma is a type of malignant proliferative disorders. Received: 28 April 2019 Accepted: 08 October 2019 Published: 12 December 2019. Keywords: Multiple myeloma survival analysis hematopoietic stem cell transplantation (HSCT) retrospective study In a variety of factors, improved renal function showed a good effect on the outcome of transplantation.Ĭonclusions: To prevent cancer relapse after autologous transplantation, it is of great significance to achieve a complete remission prior to the transplantation. The 1-year OS and PFS were 93.3% and 90.0%, respectively. The average survival time was 29.8 months and the median follow-up was 25.1 months. Results: Thirty patients with multiple myeloma were included in this study, 7 of them died because of myeloma relapse and myeloma-associated complications. A P<0.05 is considered statistically significant. Univariate and multivariate analyses were performed using Cox proportional hazards model. Kaplan-Meier was used to exhibit overall survival (OS) and progression-free survival (PFS). Methods: Patients’ information was collected by history review and follow-up through the phone call. This study was performed to analyze the possible prognostic factors for myeloma patients post stem cell transplantation. Autologous transplantation has become more and more popular because of its lower transplant-related mortality.
However, allogenic transplantation has inherent complications such as graft-versus-host disease and graft failure. Background: Hematopoietic stem cell transplantation has been applied to treat the hematologic malignancies since the 1980s.
0 kommentar(er)
